All Industries

6 Unique Benefits Of Having An Axos Invest Margin Trading Account

Benzinga

By Gerelyn Terzo, Benzinga If you’ve been investing for a while and are ready to take your portfolio to the next level, margin trading could be for you. Trading on margin is a strategy available to qualifying investors that offers many advantages. Chief among the benefits is an opportunity to increase your buying power. Without margin, you’d be limited to investing with your account balance. With the addition of margin, you gain access to borrowed funds based on the amount of cash and equities in your account. This loan, known as leverage, allows you to purchase more securities than you otherwise could without selling holdings or getting cash elsewhere. Yet another benefit of a margin account is not having to miss out on market opportunities for lack of liquidity. Everything is amplified with margin, including both potential rewards and risks. That’s why it’s so important to choose a platform that’s out for your best interests, like Axos Invest. Axos Bank was also recently named to the 2024 Forbes America’s Best Banks list in what was an otherwise tumultuous year for financial institutions. If you are interested in margin trading, Axos Invest offers many benefits that allow you to get the most out of this strategy, including the following: Low Cost One of the critical features of a margin account to grasp early is the interest rate. This represents the rate at which you pay interest on credit extended by Axos to buy, carry or trade securities. Transparency is key to avoiding surprises down the road. This is where Axos Invest shines. It offers low-cost, flexible rates with zero hidden fees, all of which are published on the company’s website. Standard rates are commensurate with debit balances: the higher the balance, the lower the rate. At Axos, your margin rate stays constant whether you’re buying securities or borrowing cash with a line of credit. Axos also offers an Elite program through which qualifying members are eligible for lower margin rates. Flexibility One of the key advantages of a margin account is that it gives you more power to chart your destiny. The nature of margin means you only have to deposit the amount you want to invest in a stock or ETF as collateral. The rest is fronted by the broker in the form of leverage, or a loan. At Axos Invest, you can borrow up to 50% of your eligible equity. Let’s use an example. Say you have $10,000 in a standard cash account with your broker. If the stock you want to buy is trading at $100 per share, you can afford a maximum of 100 shares. Now, let’s say you’ve got $10,000 in a margin account, including the value of equities. Your broker will lend you more funds, say an additional $5,000, increasing your buying power to $15,000. With the loan from your broker, you can now afford $150 shares. If the stock rises to $120 per share, you may choose to sell your holdings, repay the loan, and pocket the rest minus any fees or interest. At Axos, you gain access to a universe of stocks and ETFs from which to choose. Plus, considering the time-sensitive nature of the markets, 100% of borrowed funds are available within 24 hours. Additionally, you can use any mutual funds you own to harness more borrowing power. As long as you’ve held the funds in your account for a minimum of 30 days, you can use them to bolster the size of your portfolio and thereby your borrowing capacity. Options Trading Another benefit of having a margin account is the opportunity to trade options. There are different ways to use a margin account to participate in options trading, depending on the broker. Margin requirements for options contracts vary from broker to broker. Trading options on margin isn’t for the faint of heart, as it’s not quite as straightforward as buying stocks. It’s typically reserved for more sophisticated investors. That’s because a margin account allows you to harness more complicated options strategies that are accompanied by greater risk. Axos is among the platforms that let users trade options with a margin account and also offers Elite members a 20% discount upon approval. Diversified Portfolio It’s easy to get stuck in a rut with your portfolio, sticking with a single stock or sector. Margin trading allows you to explore more securities so that you can diversify your portfolio. A more diversified portfolio increases the chances that strong performance in one asset can offset any temporary setback in another. The best part is since you’re investing with a loan, you won’t have to sell your original holdings to achieve portfolio diversification. Loans are Available Once you’ve received the green light for a margin account, you’ll find it extremely convenient to move your funds from account to account. This means you won’t have to worry about completing paperwork every time you need additional access to funds. If you find yourself in need of a sudden cash injection, your Axos margin account can serve as a short-term line of credit, allowing you to transfer funds to various Axos accounts. Customer Support At Your Fingertips If you’re a novice investor, trading on margin might seem out of reach for you. Everybody has to start somewhere, and even experienced investors shouldn’t be afraid to ask for help. Axos Invest has a team of licensed relationship managers available to help you with your margin trading journey. The best part is these representatives are available to speak with you at no cost and for zero commission. Embrace The Margin Having a margin account opens up a world of opportunities for savvy investors looking to potentially bolster their returns. Axos checks all the boxes for investors ready to take their portfolios to the next level. Don’t hesitate to contact Axos Invest today if you are ready to embrace all the benefits that a margin account has to offer. Featured photo by nattanan23 on Pixabay. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

July 30, 2024 08:45 AM Eastern Daylight Time

Image

Citius Pharmaceuticals Nears Market Breakthrough With Two Leading Products

Benzinga

By Meg Flippin, Benzinga From fighting cancer to treating bloodstream infections, Citius Pharmaceuticals Inc. (NASDAQ: CTXR) is busy trying to solve some of the world’s ills. That’s picking up steam with two of its lead products close to commercialization. Take Mino-Lok (MLT), Citius Pharmaceuticals ' novel antibiotic lock solution that combines minocycline, ethanol and edetate disodium to treat patients with catheter-related blood stream infections. Mino-Lok offers hospitals an alternative to removing and replacing a central venous catheter (CVC), and that could reduce the number of serious adverse events like air embolism and bleeding. It could also save hospitals money. Bringing It To The Market Citius Pharmaceuticals CEO and co-founder Leonard Mazur told Benzinga that his company has “extremely positive” topline data from a Phase 3 Trial of Mino-Lok. Now Citius is meeting with the U.S. Food and Drug Administration (FDA) to move ahead with Mino-Lok, he said. Once Mino-Lok is approved, the company says it will be the only FDA-backed product for infected catheters in the market, presenting a big opportunity for the company. “The market potential is about $2 billion,” said Mazur. “Positive announcements will come out of the meeting but I can’t predict that moment.” Then there is LYMPHIR, a recombinant fusion protein designed to treat T-cell lymphomas. The drug agent combines the interleukin-2 (IL-2) receptor binding domain with diphtheria toxin fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. In 2011 and 2013, the FDA granted orphan drug designation to LYMPHIR for the treatment of peripheral T-cell lymphoma (PTCL) and Cutaneous T-cell lymphoma (CTCL). In 2021, Citius acquired an exclusive license with rights to develop and commercialize LYMPHIR in all markets except for Japan and certain other parts of Asia. In March this year, the FDA accepted Citius’s Biologics License Application (BLA) for LYMPHIR with a decision expected on August 13, the FDA's assigned Prescription Drug User Fee Act (PDUFA) action date. If approved, Citius is preparing for LYMPHIR commercialization later this year. “We’re very excited about this launching during the fourth quarter,” said Mazur. “We go from no revenue to revenues.” The executive pegged the market opportunity at $300 to $400 million, telling Benzinga LYMPHIR is an additive and won’t take market share from anyone. Shoring Up Shareholder Value Bringing two drug products to market isn't the only way Citius is enhancing shareholder value. The company is also spinning out its wholly-owned oncology unit to form Citius Oncology, a stand-alone publicly traded entity. It is doing it via a SPAC deal with TenX Keane (NASDAQ: TENK). Citius Pharma is getting 67.5 million shares in Citius Oncology at $10 per share, valuing the stake at $675 million and will retain majority ownership of approximately 90%. This transaction is expected to unlock significant value for Citius shareholders by separating the oncology business, potentially leading to increased access to capital markets and further development of new applications and additional intellectual property, reports Citius. It also underscores Citius’s strategy to purchase assets, develop them and bring them to market and then unlock shareholder value. Citius Oncology will serve as a platform to develop and commercialize novel targeted oncology therapies, with LYMPHIR the first to go to market. The company said the deal is expected to provide Citius Oncology with improved access to the public equity markets and thereby facilitate the commercialization of LYMPHIR and position the company to explore additional value-creating opportunities more fully. “The reason we are doing it is we get a Nasdaq listing by having the SPAC acquire the assets and at the same time it enables us to do something to prevent dilution for shareholders,” said Mazur. The CEO counts himself as one of them; he has invested $22.5 million of his own money in the business. “During the first year on the market we will be profitable. All that benefits Citius shareholders.” Featured photo by Nataliya Smirnova on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

July 30, 2024 08:45 AM Eastern Daylight Time

Image

Pancreatic Cancer Could Overtake Colorectal Cancer To Become Second Leading Cause Of Cancer Death – Oncolytics Is Working On A Promising Treatment

Benzinga

By Meg Flippin, Benzinga Pancreatic cancer isn’t something that only happens to those who smoke, are overweight, have a family history of the condition, or are older than 55. Increasingly, women and younger adults are getting diagnosed with this deadly form of cancer. It’s alarming, given one study found that in the U.S., the incidence of pancreatic cancer among those under the age of 55 is increasingly more rapidly than in those 55+. While pancreatic cancer is now the third leading cause of cancer deaths, by 2030, it is expected to morph into second place, surpassing colorectal cancer deaths. This year alone, about 66,440 Americans will be diagnosed with pancreatic cancer, a record for this deadly form of cancer. What’s more, about 51,750 Americans are expected to die from the disease this year. Among cancers, pancreatic is a tough one to treat. It’s a highly aggressive form of cancer that attacks the pancreas, an organ needed for digestion. With limited treatment options, the five-year survival rate is just 13%. It doesn’t help that most people are diagnosed with pancreatic cancer in a late stage when it has already spread to other parts of the body. That’s particularly true with pancreatic ductal adenocarcinoma (PDAC), which is a type of pancreatic cancer that’s created from the cells that line the ducts of the pancreas. It's one of the most lethal forms of pancreatic cancer. A person’s health, lifestyle, diet, age and family history all play a role in whether they will get this lethal disease, and changing lifestyles may be a factor in the rise in the condition’s prevalence. Given the difficulty of treating pancreatic cancer and its increasing incidence, much medical research is directed toward earlier detection and better treatments. As a result, the global pancreatic cancer market is projected to reach $7.4 billion by 2032, growing at a CAGR of 13.7% during the forecast period. Your Immune System Fired Up One area of treatment that holds promise is immunotherapies. Administered as a pill, injection, or intravenously, immunotherapies help the body’s immune system attack cancer cells. On its own, the immune system has difficulty finding and attacking cancer cells but with these therapies, it can be an avid hunter. That’s exactly what Oncolytics Biotech Inc. (NASDAQ: ONCY), the clinical-stage biopharmaceutical company specializing in immunotherapeutics for oncology, is betting will happen with pelareorep, its leading agent to fight pancreatic cancer that has demonstrated promising results in phase 1 and 2 studies. It is an intravenously delivered immunotherapeutic agent that induces anti-cancer immune responses and promotes an inflamed tumor phenotype — turning “cold” tumors “hot.” Pelareorep works by generating, recruiting and training immune cells to recognize and kill cancer while remodeling the tumor microenvironment to enable immune cell access. When added to existing treatment regimens such as chemotherapy, pelareorep demonstrates the potential to extend survival times in addition to expanding existing and new T cell clones in the blood, the company reports. Testing Under Way Pelareorep is being tested in the GOBLET study, a phase 1/2 multiple-indication study in advanced or metastatic gastrointestinal cancers conducted at 17 centers in Germany. The aim of the study, which kicked off in fall 2021, is to investigate the safety of the drug combination and improvements in tumor size. The GOBLET study was recently expanded to include a new cohort to test pelareorep and modified FOLFIRINOX (mFOLFIRINOX) with or without atezolizumab (Tecentriq®) in newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC) patients. mFOLFIRINOX is a chemotherapy treatment for pancreatic cancer that combines several drugs. The new cohort, which is testing the objective response rate (ORR) and safety, is supported by the $5 million Pancreatic Cancer Action Network (PanCAN) Therapeutic Accelerator Award. The grant was established to accelerate the development of new treatments for pancreatic cancer patients. Hitting Milestones Oncolytics Biotech recently dosed the first patient in that expanded cohort, marking a major milestone for the company. “We’re excited to begin evaluating another pelareorep combination therapy that could result in a second pancreatic cancer registration program for the company,” said Thomas Heineman, M.D., Ph.D., Chief Medical Officer at Oncolytics. “The combination of pelareorep, atezolizumab, gemcitabine and nab-paclitaxel in pancreatic cancer patients more than doubled tumor response rates compared to earlier trials of chemotherapy alone. That combination received Fast Track Designation from the FDA and is expected to be evaluated in an adaptive registration-enabling trial through the Global Coalition for Adaptive Research (GCAR). If the combination of pelareorep and mFOLFIRINOX also demonstrates a promising efficacy signal, we could have two pancreatic cancer treatment regimens on the path to registration.” The trial is being closely watched because of the promise the treatment holds if it proves successful. mFOLFIRINOX is currently considered one of two primary treatment options for many pancreatic cancer patients. If pelareorep is effective, it could broaden the population of metastatic pancreatic cancer patients who could benefit from pelareorep-based therapies, the company reports. “Oncolytics is in a favorable position as we prepare to advance multiple pelareorep programs toward registration track studies and continue to expand pelareorep’s potential as a backbone immunotherapy that can impact various tumor types,” said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics. “The ability to improve the lives of cancer patients is something that motivates everyone at Oncolytics, and beginning to treat pancreatic cancer patients in the mFOLFIRINOX cohort of GOBLET is hopefully yet another step towards that goal.” Featured photo by National Cancer Institute on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

July 30, 2024 08:35 AM Eastern Daylight Time

Image

American Battery Materials Appoints Oilfield Drilling Executive Chris McClanahan to Advisory Board

American Battery Materials Inc

American Battery Materials, Inc. (OTC: BLTH) (“ABM”, the “Company”), an environmentally responsible minerals exploration and development company focused on direct lithium extraction (“DLE”) and other critical minerals, today announced the appointment of Chris McClanahan to its Advisory Board. Mr. McClanahan brings extensive experience in the Oilfield Service industry that spans 30 plus years. Mr. McClanahan is currently President and CEO of Coastal Drilling Company, LLC, and formerly CEO and Chairman of Iron Horse Tools, LLC, operating in Texas and Louisiana. David Graber, ABM’s CEO, noted, “Chris has been an investor in our company since 2019. Having drilled thousands of wells for his own business, he is a perfect addition to ABM’s Advisory Board as we await the appropriate permitting to begin the process of further advancing ABM’s asset in Southern Utah. Chris McClanahan stated, “I have been observing the emergence of Direct Lithium Extraction (DLE) relating to mineral rich brines in the Oil and Gas industry, as defined by Exxon’s announcement into the field. The US needs to get behind a reliable domestic supply chain for critical minerals”. About American Battery Materials, Inc. American Battery Materials, Inc. (OTC: BLTH) is a U.S.-based environmentally responsible critical minerals extraction company focused on direct lithium extraction (DLE), as well as other minerals for refining, processing, and distribution to support the country’s urgent critical minerals need to bolster long-term energy transition and the electrification of the US domestic and global economy. For more information, visit www.americanbatterymaterials.com. To receive American Battery Materials, Inc. company updates via email, visit the Contact page of our website, www.americanbatterymaterials.com/contact. Forward Looking Statements To the extent that statements contained in this press release are not descriptions of historical facts regarding the Company, they are forward-looking statements reflecting the current beliefs and expectations of management. Words such as “believe,” “goal,” “plan,” “feel,” "may," "will," "expect," "anticipate," "estimate," "intend," “target” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause our future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Except as required by law, the Company undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company, please see the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 and its Quarterly Reports on Form 10-Q, including but not limited to the discussion under "Risk Factors" therein, which the Company has filed with the SEC and may be viewed at http://www.sec.gov. No Offer or Solicitation This press release shall neither constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which the offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. Contact Details Investor Relations +1 800-998-7962 ir@americanbatterymaterials.com Company Website https://www.americanbatterymaterials.com/

July 30, 2024 07:00 AM Eastern Daylight Time

StealthEX Integrates with Exchange Flow for Seamless Swaps

StealthX

Instant crypto exchange StealthEX continues to drive innovations in the cryptocurrency space. This time, the platform has partnered with Exchange Flow, a source dedicated solely to cryptocurrency exchanges, wallet providers and instant swap services. With this collaboration, StealthEX aims to offer simpler and smoother swaps and make the cryptocurrency exchange process even easier. StealthEX aims to interconnect with various exchanges, guides, and websites dedicated to cryptocurrencies. Its connection with Exchange Flow will let its users seamlessly swap digital assets thanks to the convenient StealthEX widget – without leaving Exchange Flow. StealthEX: Effortless, Private, and Limitless Crypto Swaps with No-KYC StealthEX is an instant cryptocurrency exchange platform that enables efficient crypto swaps. With StealthEX, exchanging digital assets is simple, private, non-custodial, requires neither sign-up nor verification, and is done within minutes. Even the most inexperienced users will easily navigate through the exchange procedure thanks to the platform’s simple and minimalistic design. Add to this the no-KYC policy and no upper limits on swaps, and StealthEX will undoubtedly prove to be your best choice whenever you need to exchange one crypto for another or make a fiat-to-crypto transaction. To add to the above-mentioned features, at StealthEX, more than 1500 cryptocurrencies are available for floating and fixed rates exchanges. These include such popular assets as Bitcoin (BTC), Ethereum (ETH), Monero (XMR), Tether (USDT), Litecoin (LTC), and many more, as well as an astounding amount of rare cryptocurrencies, some of which cannot be found on the majority of other exchanges, even large ones. All in all, the privacy-centric, wallet-to-wallet nature of the platform has helped it become a popular choice among crypto aficionados. Exchange Flow: Compare and Exchange Crypto Seamlessly Exchange Flow is a platform that helps its visitors discover the easiest way to compare cryptocurrency exchanges. Thanks to its extensive range of tools, any user will be able to find the perfect match for their trading needs along with comprehensive reviews, ratings, and more. The goal of the website is to provide users with the most up-to-date insights into the crypto exchange field. Thanks to the new embedded StealthEX widget, the Exchange Flow website will be able to offer its users an all-in-one crypto exchange experience. On top of comparing different cryptocurrency rates and major exchanges, you will now have direct access to cryptocurrency exchange and purchases on the Exchange Flow website. Any Exchange Flow visitor won’t need to visit third-party sites, ensuring a streamlined and secure transaction process. This will, in turn, guarantee the best user experience and increased efficiency. How Does It Work? Step-by-Step Guide It’s easy to swap as much crypto as you like via StealthEX’s efficient widget. Just go to Exchange Flow and follow these simple steps: Choose the pair and the amount you want to exchange — for instance, ETH to BTC. Press the “Start Exchange” button. Provide the wallet address you will use to receive the funds. Process the transaction. Send the deposit to the address StealthEX has generated for you. Receive coins in your wallet. StealthEX and Exchange Flow: Effortless Crypto Swaps StealthEX strives to become one of the global bridges from fiat to crypto and crypto-to-crypto, and by embedding its user-friendly widget into Exchange Flow, the platform seeks further exposure. This partnership will most certainly bring more interconnection into the cryptocurrency space and streamline the exchange process, making it easy, effortless, and problem-free. About StealthEX StealthEX is an instant cryptocurrency exchange for limitless swaps. The service is free from registration and does not store user's funds on the platform. StealthEX is the best place to buy cryptocurrency. 1500+ assets are available for quick and easy exchanges. Data privacy and security is a top priority for StealthEX, so all the swaps are non-custodial and forever will be. Contact Details Vadim Taszycki vadim@stealthex.io Company Website https://stealthex.io/

July 30, 2024 06:23 AM Eastern Daylight Time

ATFX Secures the Hong Kong SFC License, A Boost for Global Operations

500NewsWire

Hong Kong, July 30, 2024 -( 500NewsWire ) -- ATFX, a leading global CFD broker, is excited to share that they've been granted a Type 3 license from the Hong Kong Securities and Futures Commission (SFC) (Central Entity Number: BUM667). This significantly enhances ATFX’s services in the Hong Kong entity under the company name AT Global Financial Services (HK) Limited. By obtaining this license provides a solid foundation for servicing institutional professional investors in the region, also signifies both a deeper penetration into the Asian market and robust global business growth. Joe Li, Chairman of ATFX, said, “We are thrilled to have been granted the Hong Kong SFC license, which is a significant milestone for ATFX. This license not only strengthens our commitment to the Hong Kong market, but also validates our dedication to the highest regulatory standards and our unwavering focus on providing our institutional professional clients with a secure and trusted trading environment. We look forward to further expanding our presence and serving our valued Hong Kong-based clients with the exceptional service they have come to expect from ATFX.” Financial licenses are considered crucial for ensuring the efficient and effective functioning of financial institutions. ATFX proudly holds multiple prestigious licenses, including those from the UK's Financial Conduct Authority (FCA), the Cyprus Securities and Exchange Commission (CySEC), South Africa’s Financial Sector Conduct Authority (FSCA) with an ODP license, the UAE Securities and Commodities Authority (SCA), the Australian Securities and Investments Commission (ASIC), Mauritius Financial Services Commission (FSC), and the Seychelles Financial Services Authority (FSA). These regulatory endorsements ensure robust investor protection as ATFX continues to expand its influence in global financial markets. Adding the new license on the list, ATFX is poised to expand its reach in the Global market, providing a broader stage for its future endeavors. Moving forward, ATFX will further strengthen its cooperation in Hong Kong and globally, continuously improving its service quality and market competitiveness. During this critical strategic development period, ATFX has outlined an ambitious development blueprint, aiming to enhance its brand influence and leverage its unique advantages to expand into broader international markets. About ATFX ATFX is a leading global fintech broker with a local presence in 23 locations and licenses from regulatory authorities, including the UK's FCA, Cypriot CySEC, UAE's SCA, Australian ASIC, and South African FSCA. With a strong commitment to customer satisfaction, innovative technology, and strict regulatory compliance, ATFX provides exceptional trading experiences to clients worldwide. For further information on ATFX, please visit the ATFX website: https://www.atfx.com. Contact Details ATFX sales.uk@atfx.com

July 30, 2024 05:57 AM Eastern Daylight Time

Image

HackaTRON Season 7 Launches With Google Cloud as Diamond Sponsor, Celebrates Successful Kickoff at Bitcoin Nashville

TRON DAO

Geneva, Switzerland, July 29, 2024 - TRON DAO, along with co-hosts HTX DAO, BTTC, and JustLend DAO, proudly announces the launch of HackaTRON Season 7, with submissions open until October 23. Following a successful launch party at Bitcoin 2024, this season promises a series of engaging events and innovative competition tracks. Participants will have access to leading crypto VCs - TRON DAO Ventures and HTX Ventures, connect with a broad network of industry collaborators, and gain visibility among leading venture capital firms. HackaTRON Season 7 Tracks Season 7 includes five different tracks: Web3: Shape the next evolution of the internet with contributions that bridge the gap to a decentralized future. Artistry: Redefine entertainment by merging blockchain technology with gaming and NFTs, exploring new horizons for creators. DeFi: Craft the next DeFi project that makes financial services more accessible. Builder: For returning projects on TRON/BTTC that have significant updates. Integration: A new track inviting the integration of protocols, dApps, or services to enrich the TRON ecosystem. It’s an open call for developers to leverage the TRON network’s capabilities. Prize Pool Details HackaTRON Season 7 features a substantial prize pool totaling up to $650,000, which includes $500,000 in TRX, TRON's native utility token, and $150,000 in energy prizes. The energy component helps subsidize network fees, making blockchain interactions smoother and more efficient for users. The prize distribution, determined by both judge and community voting per track, is as follows: Judge-Selected Qualifiers 1st Place: $25,000 in TRX* 2nd Place: $15,000 in TRX* 3rd Place: $10,000 in TRX* 4th Place: $8,000 in TRX* 5th Place: $6,000 in TRX* Community-Selected Winners 1st Place: $7,000 in TRX* 2nd Place: $6,000 in TRX* 3rd Place: $5,000 in TRX* 4th Place: $4,000 in TRX* 5th Place: $3,000 in TRX* Additionally, there are various bonus prizes and special awards that contribute to the total prize pool of $500,000 in TRX. These bonuses recognize outstanding achievements and contributions in specific areas, encouraging diverse and innovative solutions. *All prizes are issued in TRX or TRON network Energy, not USD, restrictions applied. Sponsors Spotlight Diamond Google Cloud is the new way to the cloud, providing AI, infrastructure, developer, data, security, and collaboration tools built for today and tomorrow. Google Cloud offers a powerful, fully integrated and optimized AI stack with its own planet-scale infrastructure, custom-built chips, generative AI models and development platform, as well as AI-powered applications, to help organizations transform. Google Cloud will provide cloud service to HackaTRON S7 and partners. Gold Mobilum is a financial technology company providing various payments and banking solutions to bridge the traditional finance and web3 world. Mobilum's core mission is to make cryptocurrencies more accessible, spendable and ubiquitous in our daily lives Pentagon Games is a ZkEVM chain game publisher powering XR metaverse through deep learning and Web3. Their vision is to create immersive experiences that go beyond traditional gaming, incorporating elements of AI, AR, VR, and ZK Proof EVM blockchain technology to offer a truly integrated and interactive environment for players. GT-Protocol is a Web3 AI execution technology that provides users with access to CeFi, DeFi, and NFT crypto markets through an all-in-one conversational AI interface. Additional sponsors will be announced in the coming weeks. Stay tuned for updates. Key Dates to Remember HackaTRON S7 Submission Period: July 25 - Oct 8 Judging & Community Voting Period: Oct 24 - Oct 31 Winners Announcement: Nov 13 Demo Week: Nov 18 - Nov 22 Projects on Mainnet: Dec 3 Successful HackaTRON S7 Launch Party at Bitcoin 2024 Nashville On July 25th, The Vū Nashville, located at the iconic Movie Studio, hosted the HackaTRON Season 7 Launch Party. This event marked the commencement of HackaTRON Season 7, immersing attendees in the vibrant, cyberpunk world of TRON. The unforgettable evening featured live music, a DJ, and three hours of complimentary drinks and light bites. Guests also had the exclusive opportunity to explore the TRON merch shop. Special thanks to the HackaTRON Season 7 sponsors for making this event possible. Join Us in Shaping the Future To learn more about HackaTRON Season 7 prizes and rules and to register, please visit HackaTRON S7. About TRON DAO TRON DAO is a community-governed DAO dedicated to accelerating the decentralization of the internet via blockchain technology and dApps. Founded in September 2017 by H.E. Justin Sun, the TRON network has continued to deliver impressive achievements since MainNet launch in May 2018. July 2018 also marked the ecosystem integration of BitTorrent, a pioneer in decentralized Web3 services boasting over 100 million monthly active users. The TRON network has gained incredible traction in recent years. As of July 2024, it has over 244 million total user accounts on the blockchain, more than 8 billion total transactions, and over $20 billion in total value locked (TVL), as reported on TRONSCAN. In addition, TRON hosts the largest circulating supply of USD Tether (USDT) stablecoin across the globe, overtaking USDT on Ethereum since April 2021. The TRON network completed full decentralization in December 2021 and is now a community-governed DAO. Most recently in October 2022, TRON was designated as the national blockchain for the Commonwealth of Dominica, which marks the first time a major public blockchain partnered with a sovereign nation to develop its national blockchain infrastructure. On top of the government’s endorsement to issue Dominica Coin (“DMC”), a blockchain-based fan token to help promote Dominica’s global fanfare, seven existing TRON-based tokens - TRX, BTT, NFT, JST, USDD, USDT, TUSD, have been granted statutory status as authorized digital currency and medium of exchange in the country. TRONNetwork | TRONDAO | Twitter | YouTube | Telegram | Discord | Reddit | GitHub | Medium | Forum Media Contact Yeweon Park press@tron.network Contact Details Yeweon Park press@tron.network Company Website https://trondao.org/

July 30, 2024 12:56 AM Eastern Daylight Time

Image

News Release

Folio3 Launches Cutting-Edge Magento Development Services to Revolutionize E-Commerce Experiences

Rev Up Marketers

Folio3, a leading Magento store development company, is pleased to announce the launch of its advanced Magento development services. This initiative aims to transform e-commerce experiences through innovative solutions and industry-leading practices. With an established reputation in the field, Folio3 continues to push the boundaries of e-commerce technology. As a prominent Magento development company specializing, Folio3 has garnered extensive expertise and success in the e-commerce sector. The new Magento development services represent a strategic expansion of Folio3’s offerings, tailored to meet the evolving needs of businesses operating within the Magento ecosystem. These services are designed to enhance the functionality, performance, and user experience of Magento-powered online stores. The Magento platform is renowned for its flexibility, scalability, and robust features, making it a preferred choice for businesses seeking a comprehensive e-commerce solution. Folio3’s Magento development services leverage the full potential of this platform to deliver customized solutions that address the unique requirements of each client. The service suite includes everything from Magento store setup and configuration to advanced customization and integration with third-party systems. With a focus on delivering high-quality results, Folio3 employs a team of experienced Magento developers who possess a deep understanding of the platform’s architecture and capabilities. This expertise enables the development of bespoke solutions that not only meet but exceed client expectations. The services provided encompass various aspects of Magento development, including but not limited to, theme development, module customization, and performance optimization. The launch of these services is timely, as businesses increasingly seek to enhance their online presence and competitiveness in the digital marketplace. By integrating advanced technologies and best practices, Folio3 aims to support businesses in achieving their e-commerce goals. The company’s commitment to innovation and excellence is reflected in the meticulous approach taken towards each project, ensuring that solutions are not only effective but also future-proof. The new Magento development services are designed to cater to a diverse range of industries and business sizes, from small startups to large enterprises. This versatility underscores Folio3’s dedication to providing scalable solutions that grow with the business. Clients can expect a collaborative approach, where their specific needs and objectives drive the development process. In addition to its core Magento development offerings, Folio3 continues to maintain its position as a leading development company specializing in BigCommerce, Shopify, WooCommerce, Shopware, and Salesforce eCommerce platforms. This dual expertise allows Folio3 to offer comprehensive e-commerce solutions that cover a wide spectrum of platforms and technologies. The integration of Magento development services into the company’s portfolio further enhances its ability to serve a broader client base and address varied e-commerce requirements. The introduction of these services reflects Folio3’s ongoing commitment to advancing the field of e-commerce development. By staying at the forefront of technological advancements and industry trends, the company ensures that its clients benefit from the latest innovations and strategies. The focus on delivering high quality, customized solutions aligns with Folio3’s mission to provide exceptional value and support to businesses in their e-commerce endeavors. For more information about Folio3’s Magento development offerings and how they can benefit your business, please visit Folio3’s Magento Development Services. About Folio3: Folio3 is a prominent Magento development company known for its expertise in e-commerce solutions. With a commitment to innovation and excellence, Folio3 delivers customized development services that empower businesses to achieve their digital goals. The company’s team of experienced developers and industry specialists works collaboratively with clients to create effective, scalable solutions that enhance their online presence and drive growth. Contact Details Folio3 Mike Hassy ecommerce@folio3.com Company Website https://ecommerce.folio3.com/

July 29, 2024 12:54 PM Eastern Daylight Time

MIRA Pharmaceuticals (NASDAQ: MIRA) Reports Promising Pre-Clinical Trial Results For Mental Health Treatment, To Submit Investigational New Drug Application By End Of Year

MIRA Pharmaceuticals, Inc.

By Meg Flippin, Benzinga From cognitive impairments to depression-related illnesses, the current treatments aren’t doing enough. Sure, some may bring relief to the millions of people worldwide affected by neurological and neuropsychiatric disorders, but they come with a lot of side effects and accessibility challenges that can render them less than ideal. That leaves a gap in effective, safe and affordable solutions. MIRA Pharmaceuticals (NASDAQ: MIRA) may have the answer. This preclinical-stage pharmaceutical company is focused on transforming the treatment of mental health disorders through scientific research and technological advancements. It's betting that its two compounds, MIRA-55 and Ketamir-2, will revolutionize mental health care. Take MIRA-55 for starters. The novel compound aims to deliver the therapeutic benefits of THC and CBD without their associated side effects, such as increased appetite, paranoia and cognitive decline. It’s currently under investigation for treating neuropathic pain, anxiety and cognitive enhancements without the impurities of marijuana. In preclinical studies, MIRA-55 has shown the ability to double the memory of mice, in contrast to THC, which is known to impair memory, reports MIRA. MIRA-55 could be particularly beneficial for patients seeking cognitive enhancements and anxiety relief without the downside of impaired memory or other side effects. Meanwhile, Ketamir-2, an oral ketamine analog designed to be taken as a pill, is being investigated for its potential antidepressant effects, particularly for treatment-resistant depression (TRD) and major depressive disorder with suicidal ideation. Unlike traditional ketamine, which requires intravenous administration – posing accessibility and safety challenges – Ketamir-2 aims to simplify and improve the treatment experience. The Science Behind Ketamir-2 Recent preclinical data reveals that Ketamir-2 selectively inhibits the NMDA receptor at the PCP-binding site, avoiding interactions with opioid receptors, dopamine, serotonin transporters, and acetylcholine receptors. This unique selectivity may reduce side effects typically associated with traditional ketamine. Ketamir-2 has a 30- to 50-fold lower affinity to the PCP site compared to ketamine, which itself has about 10-fold lower affinity than PCP (Phencyclidine, Angel Dust). This is significant because ketamine was developed to be similar to PCP but with lower affinity, thereby reducing the risk of psychoactive side effects. In this respect, advocates consider Ketamir-2 a third-generation drug. Moreover, Ketamir-2 is optimized for brain delivery. It is not a substrate for P-glycoprotein (P-gp), a membrane protein that pumps drugs out of cells, including those in the brain. This characteristic could allow Ketamir-2 to have better oral absorption and penetrate the blood-brain barrier more effectively than traditional ketamine, enhancing its therapeutic potential and bioavailability. Ketamir-2's oral bioavailability is predicted to be around 80%, which is significantly higher than traditional ketamine's 30%. Preclinical studies have shown that oral Ketamir-2 is safe at high doses and effective in several antidepressant and anxiolytic models. It does not appear to induce hyper-locomotor activity – a common side effect of traditional ketamine – and has shown no interaction with the mu-opioid receptor. MIRA says this could potentially mean a reduced risk of opioid-related side effects and dependency. Recent studies further highlight Ketamir-2's anti-depressive and anxiolytic effects in a mouse model, with significant improvements in behavioral tests compared to traditional ketamine. A Step Toward Improved Patient Care If MIRA is right about Ketamir-2, it has the potential to significantly positively impact mental health care, potentially helping millions of people through improved access and affordability. Traditional ketamine treatment for depression requires a Risk Evaluation and Mitigation Strategy (REMS) protocol due to its potential for abuse and severe side effects. This involves strict regulations, including the need for intravenous administration under medical supervision, making it less accessible and more costly for patients. In contrast, Ketamir-2, as an oral formulation, aims to provide a more convenient and less intimidating treatment option, with the ease of taking a pill at home potentially leading to better adherence to treatment regimens compared to frequent hospital visits for IV infusions. By reducing the need for medical supervision and hospital visits, Ketamir-2 could enhance patient compliance and decrease overall treatment costs. Furthermore, MIRA reports that the U.S. Drug Enforcement Administration (DEA) has conducted a scientific review of both MIRA-55 and Ketamir-2 and determined that neither compound is classified as a controlled substance – significantly easing their regulatory pathway. Exploring New Frontiers: Orphan Drug Indications MIRA's journey doesn't stop at common mental health disorders. The company is exploring Ketamir-2's potential efficacy in treating chemotherapy-induced depression and cancer-related neuropathic pain. These conditions often have limited treatment options and significant patient populations in need of effective therapies. Moreover, due to its novel chemical profile, MIRA is investigating options for orphan drug indications such as multiple sclerosis-induced depression and Huntington's disease-induced depression. The company believes these rare conditions could benefit from innovative treatments like Ketamir-2. Market Potential And Patient Population The market potential for MIRA Pharmaceuticals' compounds is substantial. Cognitive impairments, including conditions like Alzheimer's disease and dementia, affect millions of individuals. Close to seven million Americans are currently living with Alzheimer's, a number expected to rise to nearly 13 million by 2050, according to the Alzheimer’s Association. Meanwhile, anxiety disorders affect over 40 million adults in the United States, according to the National Alliance on Mental Illness. For depression, particularly treatment-resistant depression, the numbers are equally staggering. Approximately 17.6 million Americans are diagnosed with major depressive disorder, with 5.5 million reporting suicidal ideation and about 2 million having suicidal ideation with intent. The annual burden of medication-treated major depressive disorder in the United States is estimated at $92.7 billion, with $43.8 billion attributable to treatment-resistant depression. Looking Ahead: The Path To Regulatory Approval MIRA Pharmaceuticals reports that it is on track to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) by the end of this year. If granted, this would pave the way for human clinical trials, bringing Ketamir-2 closer to becoming a new standard of care for neurological and neuropsychiatric disorders. The company's commitment to advancing these compounds underscores its mission to address the unmet needs of patients suffering from debilitating conditions like depression, TRD and PTSD. For more information about MIRA Pharmaceuticals and its novel compounds, visit MIRA Pharmaceuticals. Featured photo by Yuris Alhumaydy on Unsplash. MIRA Pharmaceuticals, Inc., is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. We hold exclusive license rights in the U.S., Canada and Mexico for Ketamir-2, a novel, patent pending oral ketamine analog under pre-clinical investigation to potentially deliver ultra-rapid antidepressant effects, providing hope for individuals battling treatment-resistant depression (“TRD”), major depressive disorder with suicidal ideation (MDSI), and potentially post-traumatic stress disorder (“PTSD”). The statements of the Company's management related thereto contains "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements that are not historical facts may be deemed forward-looking. These forward-looking statements include, without limitation, statements regarding the anticipated benefits of the study results described herein as well as the timing for the Company's other preclinical studies and the filing of an IND for Ketamir-2 and MIRA-55. Any forward-looking statements are based on the Company's current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond the Company's control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These and other risks concerning the Company's programs and operations are described in additional detail in Annual Report on Form 10-K for the year ended December 31, 2023 and other SEC filings, which are on file with the SEC at www.sec.gov and the Company's website at https://www.mirapharmaceuticals.com/investors/sec-filings. The Company explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Michelle Yanez Myanez@mirapharma.com Company Website http://www.mirapharmaceuticals.com/

July 29, 2024 11:30 AM Eastern Daylight Time

Image

1 ... 107 108 109 110 111 ... 3775